GLP-1 shoppers find answers in the dairy section: report
Dairy Trends Report shows people taking weight-loss drugs consume yogurt nearly three times the average
Eli Lilly cuts surprising deals with upstart biotech players
Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant obesity and diabetes franchises and enter cutting-edge […]
Semaglutide’s MASH Benefits Extend Beyond Weight Loss
(MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according…
More of Its Money and a Little Help from Washington: How Pfizer Won Metsera
Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington. Novo Nordisk has given up on trying to outbid Pfizer to acquire the obesity and metabolic drug developer after one-upping the pharma giant last week. Metsera […]
As Access to Weight Loss Medication Expands, Foodsmart’s ‘GLP-1 Companion Care’ Program Delivers Proven Medical and Pharmacy Savings through Integrated Nutrition and Lifestyle Management
SAN FRANCISCO, Nov. 10, 2025 /PRNewswire/ — Foodsmart, the leading telenutrition and foodcare provider nationwide, is expanding access to its GLP-1 Companion Care program after validating savings of $2,000 per GLP-1 patient annually versus those using medication alone. With the CMS…
Will Lower GLP-1 Prices Undermine Novo Nordisk’s Near-Term Outlook?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). Following President Trump’s comments last month on forthcoming government action to reduce the prices of Ozempic and Wegovy, Novo Nordisk disclosed last week that it has reached […]
Pfizer wins obesity drug prize, with Trump administration assist
Pfizer Inc. chief executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war , he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that evening, according to people familiar with the […]
Weight-loss pills replacing GLP-1 shots will be ready by March, Dr. Oz tells FOX Business
Oral weight loss pills will be replacing GLP-1 shots by March of 2026, Medicare and Medicaid Services Administrator Dr. Mehmet Oz predicted on Monday. Oz made the statement during a Monday morning appearance on Fox Business’ “Mornings With Maria,” where he discussed the Trump administration’s wider push to improve Americans’ health. “These pharma companies are […]
The Trump administration’s drug deals, explained
In the closing months of 2025, President Donald Trump’s effort to reshape how Americans pay for prescription drugs has taken clearer form. What started as a campaign threat to slap tariffs on pharmaceutical imports has evolved into a series of deals with some of the world’s largest drugmakers — and a promise that patients in […]
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
The heated bidding war between Pfizer PFE and Danish rival, Novo Nordisk NVO, related to the proposed acquisition of obesity drug developer Metsera MTSR is finally over. Metsera, a New York-based biotech, issued a press release stating that Pfizer has offered to acquire it for $86.25 per share (including cash and contingent value rights [CVR]) or more than $10 […]